Guardant Health Launches New Firsts: Blood Test To Track Patient’s Response To Immunotherapy, Tissue-Based Test

Guardant’s launch of a new test to track patient’s response to immunotherapy or targeted drugs and new pan-cancer tissue test, brings it closer to “one-stop-shop” in cancer care continuum.

Liquid biopsy

Guardant Health, Inc. added two new products to its portfolio, the Guardant360 Response liquid biopsy test and Guardant360 TissueNext test, the Redwood City, CA-based company announced on 22 June.

The Guardant360 Response test, which detects changes in circulating tumor DNA, can provide oncologists with insights on cancer patient’s treatment...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Oncology

More from Device Area

Fallouh Healthcare Receives Grant Funding From Innovate UK

 

Fallouh Healthcare has received £305,050 in grant funding from Innovate UK as part of the European Union’s Eureka Eurostars program. The company aims to detect cardiac tamponade, a condition that affects patients after heart surgery. Currently, there is no way to accurately diagnose the condition.

Newborn Screening Tests Among FDA Classifications

 
• By 

The US FDA has announced classifications for five device types, including four diagnostics as well as a hand cream to protect healthcare workers exposed to radiation. Two of the products are newborn screening tests.

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.